



The Company enabling Cardiac Micrograft Therapy™
Kai Kronström

Health Tuesday - 4.5.2021



This presentation is not a Company Description described in the Securities Markets Act (746/2012). This presentation is solely for information purposes and is not intended to form part of or be the basis of any decision making by its recipients. The information contained herein shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. Several risks are associated with investing in the company's shares, many of which can be significant and are related to the operating environment and nature of company. If an investor is considering investing in the company's shares, it is advisable that he or she is familiarized with the Company based on information provided at: <http://www.invesdor.com/epiheart>.

Medical need – Cardiac tissue regeneration




The medical need in detail

EFFECTIVE TREATMENT FOR ISCHEMIC MYOCARDIAL INJURIES AND HEART FAILURE




Normal Heart



Chambers relax and fill, then contract and pump.

Heart with Dilated Cardiomyopathy




Muscle fibers have stretched. Heart chambers enlarge.

Cardiac Micrograft Therapy™

OUR APPROACH EXPLAINED




EpiHeart



Clinical study results

FIRST-IN-HUMAN STUDY, WITH 6 PATIENTS



Results demonstrating (B) ventricle wall thickening, (C) Ischemic scar volume reduction

Note: The smaller number of patients in control group data is due to death of one control group patient (heart failure) prior control MRI at 6 months.



Business model:

**(1) enabling new therapy (already at clinical stage) with medical devices; and
(2) enabling epicardial delivery of additional advanced therapies**

Status

FUNDING 2021

No revenues, Invesdor & Business Finland funding closed (close to 1M€)

DEVICES


CE in Q3 2021 for critical devices (target). Devices for operating room & disposable procedure pack.

CLINICAL TRIALS SUPPORTING ADAPTATION

New study with HUS, Q3 2021 (target)

BROADER TRIAL SALES AND ADVANCED THERAPY PARTNERSHIPS

To be focused later this year



Contacts

FEEDBACK, QUESTIONS AND SUGGESTIONS ARE OPEN-HEARTEDLY WELCOMED

Kai Kronström
Co-founder, CEO
EpiHeart Oy
Haartmaninkatu 4, building 14
Helsinki, Finland
Tel. +358 40 751 6763

E-mail: kai.kronstrom@epiheart.com



Meilahti Hospital Area,
Helsinki